Date: 2016-08-08
Type of information: Private placement
Company: Fate Therapeutics (USA - CA)
Investors:
Amount: $10.3 million
Funding type: private placement
Planned used: Fate Therapeutics expects to use the proceeds from the transaction primarily to advance its pipeline of programmed cellular immunotherapies and for general corporate purposes.
Others: * On August 8, 2016, Fate Therapeutics announced that it has entered into a securities purchase agreement for a private placement with a select group of institutional investors, including funds managed by Franklin Advisers under which the investors have agreed to purchase 5,250,000 shares of the Company's common stock at a price of $1.96 per share, for gross proceeds of approximately $10.3 million. The Company did not use a placement agent in connection with the transaction. The purchase and sale is expected to close on or before August 10, 2016, subject to customary closing conditions.
The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the Securities Act), or applicable state securities laws.
Therapeutic area: Cancer - Oncology - Immunological diseases
